Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion - Trial NCT06029998
Access comprehensive clinical trial information for NCT06029998 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Utah and is currently Not yet recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Utah
Timeline & Enrollment
Phase 2
Dec 01, 2023
Dec 01, 2028
Primary Outcome
The proportion of patients achieving PSA decline of ≥ 30% from baseline will be considered a response.
Summary
The goal of this clinical trial is to test the anti-tumor activity of bortezomib in
 participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion.
 
 The main question[s] it aims to answer is if the use of bortezomib will result in a decline
 in PSA for participants.
 
 Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles. Each cycle
 is about 21 days.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06029998
Non-Device Trial